Login to Your Account

Ariad Exercises Co-Promotion Rights to Ridaforolimus

By Catherine Shaffer

Friday, March 18, 2011
Ariad Pharmaceuticals Inc., of Cambridge, Mass., elected to exercise an option in a contract with its partner Merck and Co. Inc. to co-promote the investigational drug ridaforolimus, being developed by the companies for sarcoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription